{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:31:45Z","timestamp":1777926705469,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Allogeneic stem cell transplantation (SCT) remains the only curative therapy for patients with high-risk myelodysplastic syndromes (MDS). Due to age, comorbidities, or lack of urgency, many receive only palliative therapies to improve quality of life. Some patients remain untreated due to a lack of symptoms or low progression risk. Data on the impact of palliative therapies on overall survival (OS) and leukemia-free survival (LFS) are limited. Using the D\u00fcsseldorf MDS Registry, we compared outcomes of patients receiving red blood cell transfusions (RBCT) alone to the outcome of patients receiving RBCT combined with iron chelation therapy (ICT), erythropoietin (EPO), antithymoglobulin (ATG), or lenalidomide (LENA). Matched-pairs analysis was conducted using age, gender, and prognostic scores (Revised International Prognostic Scoring System or Chronic Myelomonocytic Leukemia-specific Prognostic Scoring System). ICT-treated patients (<jats:italic>n<\/jats:italic>\u2009=\u200985) had significantly improved OS (70 vs. 21 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and lower 5-year AML progression (3.5% vs. 28.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Similar benefits were seen with EPO (<jats:italic>n<\/jats:italic>\u2009=\u2009210; OS: 63 vs. 24 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; AML: 5.7% vs. 19%, <jats:italic>p<\/jats:italic>\u2009=\u20090.007) and LENA (<jats:italic>n<\/jats:italic>\u2009=\u200930; OS: 92 vs. 57 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.049; AML: 0% vs. 16.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.024). ATG (<jats:italic>n<\/jats:italic>\u2009=\u200911) showed no significant improvement in OS (79 vs. 64 months) or AML progression (0% vs. 18.2%). While recognizing the limitations of matched-pairs analysis versus randomized trials, our findings indicate a survival benefit from ICT, EPO, or LENA versus RBCT alone. The year of diagnosis did not independently affect OS or LFS. These results support the use of selected palliative therapies to improve long-term outcomes in MDS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key points<\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Treating patients with myelodysplastic syndromes with non-curative therapies beyond red blood cell transfusions like iron chelation therapy, erythropoietin, or lenalidomide has a positive impact on overall survival and leukemia-free survival.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00277-025-06485-w","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:00:05Z","timestamp":1751000405000},"page":"3281-3288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes\u2013 a retrospective matched-pairs analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Katharina Anna","family":"Rauhe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Nachtkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"K\u00fcndgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina S.","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristoteles","family":"Giagounidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"12","key":"6485_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","volume":"35","author":"J Neukirchen","year":"2011","unstructured":"Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U (2011) Incidence and prevalence of myelodysplastic syndromes: data from the D\u00fcsseldorf MDS-registry. Leuk Res 35(12):1591\u20131596. https:\/\/doi.org\/10.1016\/j.leukres.2011.06.001","journal-title":"Leuk Res"},{"issue":"12","key":"6485_CR2","doi-asserted-by":"publisher","first-page":"24542465","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, T\u00fcchler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, Bennett JM, Bowen D, Fenaux P, Francois D, Kantarjian H, K\u00fcndgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Mciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilst\u00f6cker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loodsrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):24542465. https:\/\/doi.org\/10.1182\/blood-2012-03-420489","journal-title":"Blood"},{"issue":"15","key":"6485_CR3","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L, Cervera J, K\u00fcndgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luno E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G (2013) Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 121(15):3005\u20133015. https:\/\/doi.org\/10.1182\/blood-2012-08-452938","journal-title":"Blood"},{"issue":"3","key":"6485_CR4","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.3324\/haematol.2013.101055","volume":"99","author":"E Zipperer","year":"2014","unstructured":"Zipperer E, Tanha N, Strupp C, K\u00fcndgen A, Nachtkamp K, Neukirchen J, Hildebrandt B, Haas R, Gattermann N, Germing U (2014) The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica 99(3):e31\u2013e32. https:\/\/doi.org\/10.3324\/haematol.2013.101055","journal-title":"Haematologica"},{"issue":"2","key":"6485_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00277-020-04325-7","volume":"100","author":"A Kasprzak","year":"2021","unstructured":"Kasprzak A, Nachtkamp K, Kondakci M, Schroeder T, Kobbe G, K\u00fcndgen A, Kaivers J, Rautenberg C, Haas R, Gattermann N, Bonadies N, Germing U (2021) Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes. Ann Hematol 100(2):455\u2013463. https:\/\/doi.org\/10.1007\/s00277-020-04325-7","journal-title":"Ann Hematol"},{"issue":"8","key":"6485_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","volume":"36","author":"J Neukirchen","year":"2012","unstructured":"Neukirchen J, Fox F, K\u00fcndgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N (2012) Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the D\u00fcsseldorf MDS registry. Leuk Res 36(8):1067\u20131070. https:\/\/doi.org\/10.1016\/j.leukres.2012.04.006","journal-title":"Leuk Res"},{"key":"6485_CR7","first-page":"464","volume":"30","author":"M J\u00e4ger","year":"1992","unstructured":"J\u00e4ger M, Aul C, S\u00f6hngen D, Germing U, Schneider W (1992) Sekund\u00e4re h\u00e4mochromatose bei polytransfundierten patienten mit myelodysplastischen syndromen. Beitr Infusionsther 30:464\u2013468 German","journal-title":"Beitr Infusionsther"},{"issue":"4","key":"6485_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00277-008-0588-3","volume":"88","author":"G Metzgeroth","year":"2009","unstructured":"Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J (2009) Deferasirox in MDS patients with transfusion-caused iron overload - a phase-II study. Ann Hematol 88(4):301\u2013310. https:\/\/doi.org\/10.1007\/s00277-008-0588-3","journal-title":"Ann Hematol"},{"issue":"1","key":"6485_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s12885-021-08259-9","volume":"21","author":"LSA Chan","year":"2021","unstructured":"Chan LSA, Gu LC, Wells RA (2021) The effects of secondary iron overload and iron chelation on a radiation-induced acute myeloid leukemia mouse model. BMC Cancer 21(1):509. https:\/\/doi.org\/10.1186\/s12885-021-08259-9","journal-title":"BMC Cancer"},{"issue":"7","key":"6485_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00277-008-0450-7","volume":"87","author":"V Moyo","year":"2008","unstructured":"Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S (2008) Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes. Ann Hematol 87(7):527\u2013536. https:\/\/doi.org\/10.1007\/s00277-008-0450-7","journal-title":"Ann Hematol"},{"issue":"3","key":"6485_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00277-004-0961-9","volume":"84","author":"MA Spiriti","year":"2005","unstructured":"Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzar\u00e0 A, Pagnini D, D\u2019Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC (2005) Impact of a new dosing regimen of Epoetin Alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84(3):167\u2013176. https:\/\/doi.org\/10.1007\/s00277-004-0961-9","journal-title":"Ann Hematol"},{"issue":"3","key":"6485_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.tracli.2015.04.001","volume":"22","author":"MF Murphy","year":"2015","unstructured":"Murphy MF, Goodnough LT (2015) The scientific basis for patient blood management. Transfus Clin Biol 22(3):90\u201396. https:\/\/doi.org\/10.1016\/j.tracli.2015.04.001","journal-title":"Transfus Clin Biol"},{"issue":"6","key":"6485_CR13","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1097\/hs9.0000000000000314","volume":"3","author":"U Germing","year":"2019","unstructured":"Germing U, Oliva EN, Hiwase D, Almeida A (2019) Treatment of anemia in transfusion dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. Hemasphere 3(6):e314. https:\/\/doi.org\/10.1097\/hs9.0000000000000314","journal-title":"Hemasphere"},{"issue":"2","key":"6485_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","volume":"111","author":"S Park","year":"2008","unstructured":"Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mah\u00e9 B, Ferrant A, Ravoet C, Escoffre-Barbe M, Ad\u00e8s L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111(2):574\u2013582. https:\/\/doi.org\/10.1182\/blood-2007-06-096370","journal-title":"Blood"},{"issue":"8","key":"6485_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.leukres.2008.12.019","volume":"33","author":"K Nachtkamp","year":"2009","unstructured":"Nachtkamp K, K\u00fcndgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N, Haas R, Germing U (2009) Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33(8):1024\u20131028. https:\/\/doi.org\/10.1016\/j.leukres.2008.12.019","journal-title":"Leuk Res"},{"issue":"4","key":"6485_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.seminhematol.2012.07.004","volume":"49","author":"AR Parikh","year":"2012","unstructured":"Parikh AR, Olnes MJ, Barrett AJ (2012) Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol 49(4):304\u2013311. https:\/\/doi.org\/10.1053\/j.seminhematol.2012.07.004","journal-title":"Semin Hematol"},{"issue":"1","key":"6485_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ajh.2830050104","volume":"5","author":"M Amare","year":"1978","unstructured":"Amare M, Abdou NL, Robinson MG, Abdou NI (1978) Aplastic anemia associated with bone marrow suppressor T-cell hyperactivity: successful treatment with antithymocyte Globulin. Am J Hematol 5(1):25\u201332. https:\/\/doi.org\/10.1002\/ajh.2830050104","journal-title":"Am J Hematol"},{"issue":"14","key":"6485_CR18","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","volume":"2","author":"M Stahl","year":"2018","unstructured":"Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM (2018) The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv 2(14):1765\u20131772. https:\/\/doi.org\/10.1182\/bloodadvances.2018019414","journal-title":"Blood Adv"},{"issue":"11","key":"6485_CR19","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/sj.leu.2403124","volume":"17","author":"S Yazji","year":"2003","unstructured":"Yazji S, Giles FJ, Tsimberidou A-M, Estey EH, Kantarjian HM, O\u2019Brien SA, Kurzrock R (2003) Antithymocyte Globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17(11):2101\u20132106. https:\/\/doi.org\/10.1038\/sj.leu.2403124","journal-title":"Leukemia"},{"issue":"15","key":"6485_CR20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/jco.2007.11.9214","volume":"26","author":"EM Sloand","year":"2008","unstructured":"Sloand EM, Wu CO, Greenberg P, Young N, Barrett J (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26(15):2505\u20132511. https:\/\/doi.org\/10.1200\/jco.2007.11.9214","journal-title":"J Clin Oncol"},{"issue":"3","key":"6485_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","volume":"99","author":"JJ Molldrem","year":"1997","unstructured":"Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ (1997) Antithymocyte Globulin for patients with myelodysplastic syndrome. Br J Haematol 99(3):699\u2013705. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.4423249.x","journal-title":"Br J Haematol"},{"issue":"3","key":"6485_CR22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/sj.leu.2403239","volume":"18","author":"M Stadler","year":"2004","unstructured":"Stadler M, Germing U, Kliche K-O, Josten KM, Kuse R, Hofmann W-K, Schrezenmeier H, Novotny J, Anders O, Eimermacher H, Verbeek W, Kreipe HH, Heimpel H, Aul C, Ganser A (2004) A prospective, randomised, phase II study of horse antithymocyte Globulin vs rabbit antithymocyte Globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18(3):460\u2013465. https:\/\/doi.org\/10.1038\/sj.leu.2403239","journal-title":"Leukemia"},{"issue":"7","key":"6485_CR23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"issue":"14","key":"6485_CR24","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Ca\u00f1izo C, Guerci-Bresler A, Nilsson L, Platzbecker U, L\u00fcbbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellstr\u00f6m-Lindberg E (2011) A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118(14):3765\u20133776. https:\/\/doi.org\/10.1182\/blood-2011-01-330126","journal-title":"Blood"},{"issue":"7","key":"6485_CR25","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/leu.2015.340","volume":"30","author":"E Schuler","year":"2016","unstructured":"Schuler E, Giagounidis A, Haase D, Shirneshan K, B\u00fcsche G, Platzbecker U, Nolte F, G\u00f6tze K, Schlenk RF, Ganser A, Letsch A, Braulke F, L\u00fcbbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U (2016) Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia 30(7):1580\u20131582. https:\/\/doi.org\/10.1038\/leu.2015.340","journal-title":"Leukemia"},{"issue":"5","key":"6485_CR26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/leu.2012.369","volume":"27","author":"A K\u00fcndgen","year":"2013","unstructured":"K\u00fcndgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U (2013) Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 27(5):1072\u20131079. https:\/\/doi.org\/10.1038\/leu.2012.369","journal-title":"Leukemia"},{"issue":"9","key":"6485_CR27","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/leu.2016.111","volume":"30","author":"M Mossner","year":"2016","unstructured":"Mossner M, Jann J-C, Nowak D, Platzbecker U, Giagounidis A, G\u00f6tze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G, L\u00fcbbert M, Ganser A, B\u00fcsche G, Schuler E, Nowak V, Pressler J, Obl\u00e4nder J, Fey S, M\u00fcller N, Lauinger-L\u00f6rsch E, Metzgeroth G, Wei\u00df C, Hofmann W-K, Germing U, Nolte F (2016) Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the German MDS study group (GMDS). Leukemia 30(9):1956\u20131959. https:\/\/doi.org\/10.1038\/leu.2016.111","journal-title":"Leukemia"},{"issue":"4","key":"6485_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","volume":"26","author":"RK Schneider","year":"2014","unstructured":"Schneider RK, Adem\u00e0 V, Heckl D, J\u00e4r\u00e5s M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Sol\u00e9 F, Ebert BL (2014) Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26(4):509\u2013520. https:\/\/doi.org\/10.1016\/j.ccr.2014.08.001","journal-title":"Cancer Cell"},{"issue":"7","key":"6485_CR29","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/evidoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Gundem G, Medina-Martinez JS, Domenico D, J\u00e4dersten M, Germing U, Sanz G, van de Loosdrecht AA, Kosmider O, Follo MY, Thol F, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase D, Ganster C, Ades L, Tobiasson M, Palomo L, Della Porta MG, Takaori-Kondo A, Ishikawa T, Chiba S, Kasahara S, Miyazaki Y, Viale A, Huberman K, Fenaux P, Belickova M, Savona MR, Klimek VM, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sol\u00e9 F, Platzbecker U, Heuser M, Valent P, Ohyashiki K, Finelli C, Voso MT, Shih L-Y, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L, Cazzola M, Ogawa S, Hellstr\u00f6m-Lindberg E, Papaemmanuil E (2022) Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid 1(7):EVIDoa2200008. https:\/\/doi.org\/10.1056\/evidoa2200008","journal-title":"NEJM Evid"},{"issue":"15","key":"6485_CR30","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/jco.22.01784","volume":"41","author":"E Sauta","year":"2023","unstructured":"Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao L-P, Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, D\u2019Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG (2023) Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol 41(15):2827\u20132842. https:\/\/doi.org\/10.1200\/jco.22.01784","journal-title":"J Clin Oncol"},{"issue":"12","key":"6485_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3238\/arztebl.m2023.0005","volume":"120","author":"K Nachtkamp","year":"2023","unstructured":"Nachtkamp K, Kobbe G, Gattermann N, Germing U (2023) Myelodysplastic syndromes - New methods of diagnosis, prognostication, and treatment. Dtsch Arztebl Int 120(12):203\u2013210. https:\/\/doi.org\/10.3238\/arztebl.m2023.0005","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"6485_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood.2019000942","volume":"136","author":"AJ Mennsen","year":"2020","unstructured":"Mennsen AJ, Walter MJ (2020) Genetics of progression from MDS to secondary leukemia. Blood 136(1):50\u201360. https:\/\/doi.org\/10.1182\/blood.2019000942","journal-title":"Blood"},{"issue":"9","key":"6485_CR33","doi-asserted-by":"publisher","first-page":"e70014","DOI":"10.1002\/hem3.70014","volume":"8","author":"P Mazzeo","year":"2024","unstructured":"Mazzeo P, Ganster C, Wiedenh\u00f6ft J, Shirneshan K, Rittscher K, Brzuszkiewicz EB, Steinemann D, Schieck M, M\u00fcller-Thomas C, Treiber H, Braulke F, Germing U, Sockel K, Balaian E, Schanz J, Platzbecker U, G\u00f6tze KS, Haase D (2024) Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS. Hemasphere 8(9):e70014. https:\/\/doi.org\/10.1002\/hem3.70014","journal-title":"Hemasphere"},{"issue":"23","key":"6485_CR34","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1002\/cncr.30917","volume":"123","author":"J Neukirchen","year":"2017","unstructured":"Neukirchen J, Lauseker M, Hildebrandt B, Nolting AC, Kaivers J, Kobbe G, Gattermann N, Haas R, Germing U (2017) Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis. Cancer 123(23):4608\u20134616. https:\/\/doi.org\/10.1002\/cncr.30917","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06485-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06485-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06485-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:00:34Z","timestamp":1753171234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06485-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6485"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06485-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Heinrich-Heine University Duesseldorf (March 2022, No. 3973).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed consent for registry studies as part of their initial diagnosis process.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"K.A.R., A.K., C.S., A.K., S.D., W.-K.H., and A.G. have no conflicts of interest to declare. F.S. received travel support from Jazz Pharmaceuticals. K.N. received travel support from Medac, honoraria from Jazz Pharmaceuticals and was part of an advisory board from BMS. K.M. received speakers\u2019 honoraria from BMS and Novartis. K.S.G. received honoraria and was part of advisory boards from BMS and Abbvie. N.G. received speakers\u2019 honoraria from Novartis and BMS and research support from Takeda. U.G. received speakers\u2019 honoraria from Novartis, Jansen, and BMS and research support from BMS, Abbvie, and Jazz Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}